OUR QUEST Advancing medicines Solving therapeutic problems Improving lives 12 years. 2+ billion doses and counting. Our pipeline of medicines aims to overcome barriers that patients face with existing treatment options and provide new paradigms for treating critical and complex conditions.1 See our pipeline 1 2 Pipeline Aquestive Therapeutics is the undisputed leader in developing and delivering medications via film, through our proprietary PharmFilm® technology. We’ve used our expertise to create a robust, proprietary CNS and complex molecule portfolio. Learn about the medicines we’re reinventing to improve treatment options for patients. See our pipeline Innovative Drug Delivery PharmFilm® is a versatile, high-performance drug delivery technology that can be uniquely tailored to achieve a desired product profile with optimized absorption, bioavailability, and onset of action. See how Aquestive is changing drug delivery to deliver meaningful clinical and therapeutic advances. Learn about PharmFilm® technology Commitment to Epilepsy Our innovations in oral drug delivery aim to improve the treatment experience for patients with epilepsy and their caregivers who struggle with difficult or invasive modes of administration, complex treatment regimens, and inconsistent dosing and drug delivery.2 Our efforts to help patients and families extend beyond the clinic. Find out how We are committed to you Click here to view a message from Chief Executive Officer, President and Director of Aquestive Therapeutics, Inc. about COVID-19 Read More Advancing medicines Solving therapeutic problems Improving lives Aquestive is a pharmaceutical company that advances and commercializes medicines to solve therapeutic problems and meaningfully improve people’s lives. We apply innovative drug delivery technology and scientific expertise to redesign important medicines. Our initial focus, supported by our current approved products and late-stage pipeline, is to improve medications and outcomes for patients with central nervous system (CNS) conditions. Our success is proven 2B+ PharmFilm® doses consumed by patients 200+ Worldwide patents 4 Continents where our products are sold Aquestive works hand-in-hand with our partners to address their toughest challenges—enhancing existing molecules and providing a development platform for new ones. We have comprehensive capabilities to advance medicines from pipeline to market. Partners can rely on our scientific and regulatory expertise, integrated development capabilities, and world-class clinical and commercial manufacturing operations. More than 2 billion commercial doses have been delivered with our PharmFilm® technology. News Articles Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference WARREN, N.J. , Nov. 17, 2021 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQ… Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance Libervant™ (diazepam) Buccal Film continues to progress through the FDA review process in advance of… 1 2 Newsroom References 1. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67–76. 2. Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in seizure emergencies: a systematic review. Epilepsy Behav. 2016;63:109–117. Contact Us About Us Our Medicines Pipeline Innovative Drug Delivery Collaborations Investors Careers Newsroom Images of individuals were purchased by Aquestive® Therapeutics and are intended to model real patient scenarios. © 2020 Aquestive Therapeutics, Inc. PharmFilm®, Sympazan®, and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All rights reserved. Terms of Use Privacy Policy Corporate Governance Code of Conduct California Compliance Declaration California Consumer Privacy Policy Sitemap This site uses cookies to store information on your computer. Some are essential to make our site work; others help us improve the user experience. By using the site, you consent to the placement of these cookies. OkLearn More